ArticleJournal of medical biochemistry2026
Impact of MMC-assisted glycemic control assistant on biochemical indicators of glucose metabolism in type 2 diabetes: A retrospective study.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective glycemic management in type 2 diabetes remains challenging due to limited patient self-management and fragmented care. The National Standardized Metabolic Management Center (MMC)-assisted glycemic control assistant is a novel digital platform that integrates real-time monitoring, education, and treatment adjustment. This study evaluated its impact on biochemical markers and patient behaviors compared with routine care. Methods: A retrospective study was conducted on 160 patients with type 2 diabetes, including 95 who received MMC-assisted digital management and 65 who received routine care. Key biochemical parametersfasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), and glycated hemoglobin (HbA1c)were measured using standardized enzymatic assays. Dietary behavior and diabetes self-management were also assessed using validated scales. Results: At baseline, groups were comparable in clinical and behavioral characteristics. After intervention, the MMC group achieved greater improvements: FPG decreased by 10.1% (7.42± 2.43 vs. 8.30± 2.66 mmol/L, P= 0.032), 2hPG by 17.5% (10.23± 3.21 vs. 12.39± 3.50 mmol/L, P < 0 .0 0 1 ), and HbA1c by 9.0% (7.26 ± 2.05 % vs. 7.98± 2.34% , P = 0.041). Significant gains were also observed in dietary behavior and adherence to glucose monitoring, medication, and exercise. Conclusions: The MMC-assisted glycemic control assistant enhances glycemic control and promotes healthier behaviors in type 2 diabetes. These findings support its clinical utility and highlight the potential for broader integration of digital tools into standardized chronic disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.